The Public Cannabis Company Revenue Tracker, managed by New Cannabis Ventures, ranks the top revenue producing cannabis stocks that generate industry sales of more than $2.5 million per quarter. This data-driven, fact-based tracker will continually update based on new filings so that readers can stay up to date. Companies must file with the SEC or SEDAR to be considered for inclusion.

Fifteen companies currently qualify for inclusion, with six filing in U.S dollars and nine in the Canadian currency. Over the past several days, the top three Canadian LPs in terms of quarterly revenue all reported quarters ending 12/31/17. Last week, Aurora Cannabis (TSX: ACB) (OTC: ACBFF) reported quarterly sales of C$11.7 million for its FY18-Q2, representing growth of 201%. Earlier this week, MedReleaf (TSX: LEAF) (OTC: MEDFF) reported sales of C$11.35 million for its FY18-Q3, representing growth of 9%, while Canopy Growth (TSX: WEED) (OTC: TWMJF) reported C$21.7 million sales for its FY18-Q3, representing growth of 123%.

In addition, GW Pharma (NASDAQ: GWPH) reported $7.74 million sales for its FY18-Q1 ending December 31st earlier this month, which represented growth 169% but was inflated by one-time factors related to the termination of a research and collaboration agreement with Otsuka Pharma, which gave back the rights to Sativex.

In March, Isodiol International (CSE: ISOL) (OTC: ISOLF) and MPX Bioceutical (CSE: MPX) (OTC: MPXEF) are expected to report its FY18-Q3 results for the quarter ending December 31st by March 1st. Terra Tech (OTC: TRTC) is expected to report its annual financials for 2017 by March 16th. CanniMed Therapeutics (TSX: CMED) (OTC: CMMDF) would ordinarily report its FY18-Q1 results for the quarter ending January 31st by March 17th, though it may not do so if its acquisition by Aurora Cannabis has closed. CV Sciences (OTC: CVSI) and Grow Generation (OTC: GRWG) are expected to report 2017 financials by April 2nd. Finally, while CannTrust (CSE: TRST) (OTC: CNTTF) isn’t required to report its 2017 financials until late April, we expect it to do so by the end of March. The company has already reported preliminary Q4 sales of $7 million.

Visit the Public Cannabis Company Revenue Tracker to see the complete list of qualifying companies.

Exclusive article by Alan Brochstein, CFA

Based in Houston, Alan leverages his experience as founder of online community 420 Investor, the first and still largest due diligence platform focused on the publicly-traded stocks in the cannabis industry. With his extensive network in the cannabis community, Alan continues to find new ways to connect the industry and facilitate its sustainable growth. At New Cannabis Ventures, he is responsible for content development and strategic alliances. Before shifting his focus to the cannabis industry in early 2013, Alan, who began his career on Wall Street in 1986, worked as an independent research analyst following over two decades in research and portfolio management. A prolific writer, with over 650 articles published since 2007 at Seeking Alpha, where he has 70,000 followers, Alan is a frequent speaker at industry conferences and a frequent source to the media, including the NY Times, the Wall Street Journal, Fox Business, and Bloomberg TV. Contact Alan: Twitter | Facebook | LinkedIn | Email